DBS sets HKD 17.80 target for 3SBio stock on October 16, 2026

Published on 10/17/2026 at 21:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Adjusted profit rose 26.50 percent in first-half 2026. 3SBio stock stood at HKD 14.47 on October 16, 2026, up 0.77 percent.

Analyst view and earnings

DBS Bank set a HKD 17.80 target for 3SBio on October 16, 2026.
Adjusted operating profit rose 26.50 percent in the first half of 2026.
3SBio stock stood at HKD 14.47 at 4:08 p.m. HKT on October 16, 2026, up 0.77 percent versus the prior close of October 15, 2026.
TradingView lists March 30, 2027 as the next earnings date.

3SBio, KYG8875G1029, Illustration mit AI erstellt.

DBS Bank initiated coverage of 3SBio with a Buy rating and a HKD 17.80 price target on October 16, 2026, according to Futunn. Against the HKD 14.47 last price, the target is 23.01 percent higher. 3SBio stock last stood at HKD 14.47 on October 16, 2026 at 4:08 p.m. HKT, up 0.77 percent versus the prior close of October 15, 2026.

First-half profit mix matters

The latest reported period points to a split operating picture. A September 22 analysis on Futunn said revenue reached RMB 4.526 billion in the first half of 2026, up 3.90 percent year over year. Adjusted operating profit attributable to equity holders rose 26.50 percent to RMB 1.436 billion, while net profit attributable to equity holders fell 15.60 percent to RMB 1.147 billion.

Stock near its yearly low

The HKEX quote placed 3SBio between a 52-week low of HKD 14.09 and a high of HKD 35.42 as of October 16, 2026. At HKD 14.47, the stock was 2.70 percent above its yearly low and 59.15 percent below its yearly high. Trading volume was 17,756,596 shares against an average of 21,566,381 shares.

Valuation and next earnings date

3SBio had a market capitalization of HKD 36.2 billion and a price-to-earnings ratio of 3.72 as of October 16, 2026. The trailing dividend yield was 0.02 percent. TradingView lists March 30, 2027 as the next earnings date, although the finance calendar identifies that date as the next scheduled report.

Comparison with peers

3SBio (HKEX, HKD): plus 0.77 percent, P/E 3.72, market capitalization HKD 36.2 billion
BeOne Medicines (HKEX, HKD): plus 4.36 percent, P/E 65.31, market capitalization HKD 305.0 billion
Innovent Biologics (HKEX, HKD): plus 1.48 percent, P/E 113.34, market capitalization HKD 155.3 billion

Trading position

For investors, the key contrast is between the low earnings multiple and the uneven first-half profit picture. The analyst target gives the stock a dated valuation marker, while the 52-week position keeps the recent market range central to the report.

3SBio stock last stood at HKD 14.47 on October 16, 2026 at 4:08 p.m. HKT, up 0.77 percent versus the prior close of October 15, 2026.